An ethno-bridging study of Pergoveris in healthy premenopausal participants of Japanese or Caucasian

  • Research type

    Research Study

  • Full title

    A Phase 1, open label, single dose, parallel-group study to investigate the pharmacokinetics of the fixed combination of 900 IU r hFSH and 450 IU r hLH given as Pergoveris®, administered subcutaneously in pituitary-suppressed healthy premenopausal female participants of Japanese or Caucasian origins

  • IRAS ID

    1012476

  • Contact name

    Communication Center Merck KGaA

  • Contact email

    CTIS-GRA@merckgroup.com

  • Sponsor organisation

    Merck Healthcare KGaA

  • Clinicaltrials.gov Identifier

    NCT07269327

  • Research summary

    Pergoveris is a fixed combination product consisting of r hFSH and r hLH - synthetic forms of two hormones FSH (follicle stimulating hormone) and LH (luteinising hormone) - in a ratio 2:1, for the stimulation of follicular development in women with severe LH and FSH deficiency. Disorders leading to reduced LH and FSH may lead to the absence of adequate ovulation, resulting in infertility and anovulation is estimated to account for up to 24% of human infertility problems. This is a Phase 1, open-label, single dose, parallel-group study where a fixed combination of 900 IU r hFSH and 450 IU r hLH given as Pergoveris, administered subcutaneously (an injection under the skin) in premenopausal female participants of Japanese or Caucasian origin. Prior to dosing, the participants are administered the combined oral contraceptive Marvelon. This suppresses the pituitary (a gland at the base of the brain) such that the hormones aren’t produced naturally, a process called downregulation.
    The aim of this ethno-bridging study is to investigate the levels in the blood of both r-hFSH and r-hLH in Caucasian and Japanese participants to address any potential ethnic effect and to support the registration of Pergoveris solution for injection in a prefilled pen in Japan.
    Approximately 24 (12 Japanese, 12 Caucasian) healthy female participants, meeting the eligibility criteria after confirming downregulation, will receive a single dose of Pergoveris on Day 1. The group of Caucasian participants will be matched by mean body weight (± 20% body weight [kg]) and mean age (± 10 years) to the group of Japanese participants as assessed at Day 1.
    The study duration is approximately 9 weeks. Participants will visit the clinic once during screening period, twice during the 4-week downregulation period and will stay in the clinical research unit from Day -1 until the end of the study on Day 8.

  • REC name

    London - Harrow Research Ethics Committee

  • REC reference

    25/LO/0542

  • Date of REC Opinion

    1 Oct 2025

  • REC opinion

    Further Information Favourable Opinion